We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Hope for Patients with Chronic Diarrhea

By HospiMedica International staff writers
Posted on 26 Oct 2014
A pilot study suggests that obeticholic acid (OCA) may reduce symptoms of chronic diarrhea in patients suffering from bile acid diarrhea (BAD).

Researchers at Imperial College London (United Kingdom) conducted a study to test OCA in three groups: 10 patients with primary BAD, where the intestine is otherwise healthy; 10 with secondary BAD, where malabsorption can occur as a result of another disease, such as Crohn's; and 8 others with chronic diarrhea who served as controls. More...
The patients recorded their symptoms for two weeks before starting OCA treatment, for two weeks while taking the drug daily, and for two weeks afterwards. Blood tests were taken before and after the OCA treatment period.

The results showed that in primary BAD, OCA use resulted in a 24% reduction in median stool frequency and a 34% reduction in diarrhea index after two weeks of treatment. In the secondary BAD group, significant clinical improvements were found predominantly in patients with shorter ileal resections; symptoms of abdominal pain and urgency also improved. In the control group there was no significant clinical improvement. The treatment was generally well tolerated. The study was published on October 20, 2014, in Alimentary Pharmacology and Therapeutics.

“Many doctors are totally unaware of bile acid diarrhea, but it's more common than Crohn's disease and ulcerative colitis,” said lead author Prof. Julian Walters, MD, of the Imperial College London department of medicine. “This drug represents a new potential approach to treating BAD by restoring the levels of the FGF19 hormone and so controlling bile acid production in the liver.”

BAD is caused by excessive secretion of bile acids—normally absorbed in the ileum—into the intestine, which passes into the colon and causes watery diarrhea. It is estimated to affect 1 in 100 adults in western countries, but is often mistaken for irritable bowel syndrome (IBS). BAD often has a serious impact on patients' work and social lives, causing them to have up to 10 watery bowel movements a day, often for many months, with an urgent need to go to avoid accidental incontinence.

An inhibitory regulator hormone produced in the ileum, ileal hormone fibroblast growth factor 19 (FGF19), regulates hepatic bile acid synthesis, and is secreted in response to farnesoid X receptor (FXR) activation. Patients with BAD have low levels of FGF19, and thus OCA, the first in the new class of FXR agonists, can target the production of bile acid.

Related Links:

Imperial College London



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.